Cancer

Cancer refers to a group of more than a hundred diseases that can originate in many different parts of the body. Cancer begins in your cells, which are the building blocks of your body.

Metabolic Flexibility in Cancer: How Diet and Nutrition Shape Tumor Survival and Resistance

Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, microenvironmental stress, and therapeutic pressure. This article explains how dietary interventions may exploit metabolic flexibility and plasticity to enhance treatment response while accounting for tumor heterogeneity.

The Biochemistry of Breast Cancer Screening

Discovery of Blood Cancer Cells that show Plasma Cell-Like Differentiation

Cancer Plasticity: The Shape-Shifting Threat Challenging Modern Treatments

What Causes Cancer?

Why are Cancer Cell Lines Useful?

Cancer Pain

Hypoxia Markers and Their Importance

Transforming Cancer Care through Genomic Testing

Assay for Monitoring and Treating Malignant Brain Tumors

Hot vs Cold: the differences between tumor types

Cancer Pathophysiology

See more featured articles »

Metastatic Migration in Cancer may be Influenced by Metabolism

Cancer Diagnosis

Living with Cancer Pain

Microfluidic cancer treatment screen combined with flow cytometry

Secondary Brain Cancer

Cancer History

Cancer Epidemiology

What is Immunochemotherapy?

Cancer Classification

Cured Meats, Nitrates, and Cancer Risk: Why Food Source and Processing Matter

Myc Mutations and Cancer

Effects of Social and Economic Deprivation on Cancer Mortality

CDK9 and Cancer

What Role do Biobanks Play in Cancer Research?

Cancer Research

Nanostructured toxins for the selective destruction of drug-resistant human CXCR4style+ colorectal cancer stem cells

The Cancer Cell Surface Proteome as a Therapeutic Target

Overview of Cell Viability and Cytotoxicity

Insights into Oncofertility

Cancer Prevention: Lowering your Risk

What is Cancer of Unknown Primary?

Insight into Cancer Vaccines

Cancer Pain Management

Exploiting Enzymes in Cancer Diagnosis and Therapy

Secondary Lung Cancer

Tyrosine Kinase Inhibitors for Targeted Cancer Therapy

Cutaneous Manifestations of Internal Malignancy

Using Biomarkers to Detect Cancer

The Effects of Cancer on Family Life

Extracellular Vesicles as Floating Cancer Biomarkers

Investigating the Molecular Mechanisms of Cancer

Cancer Screening Considerations: Balancing the Benefits and Risks

How Camomile Could Prevent Neutropenia in Pediatric Leukemia Patients

What is Cancer?

Proto-Oncogene Activation: The Genetic Shift that Fuels Cancer

What is the Tumor Microenvironment?

Cancer Symptoms

Acidosis and Tumor Progression

TARDIS: The Improved Method of Detecting Breast Cancer

Caring for a Loved One with Cancer

What is Merkel Cell Carcinoma?

How Immune Checkpoint Inhibitors have Revolutionized Cancer Treatment

Cancer Management

Pediatric Cancer

Cancer Prognosis

British Pioneers in Cancer Biology

Cancer Glossary

Is Cancer a Metabolic Disorder?

What is Tumorigenesis?

Targeted Cancer Therapies

Latest Cancer News and Research

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

In pooled prospective data from 977,282 UK adults, preferring tea or coffee “very hot” was associated with more than threefold higher risk of esophageal squamous cell carcinoma compared with preferring drinks “warm,” while drink temperature showed no material association with adenocarcinoma risk. Consuming six or more hot drinks daily was independently associated with higher squamous cell carcinoma risk, and modeling estimated that about 440 UK cases each year could be prevented by switching from “very hot” to “hot” drinks if the association is causal.

14 Sep 2026

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

14 Sep 2026

Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

A laboratory study tested how ultra-processed, unprocessed, and mixed diets affected survival in 127 lobster cockroaches, Nauphoeta cinerea. Cockroaches fed only ultra-processed foods had higher mortality than those given unprocessed or mixed diets, although the study could not determine whether processing, ingredients, nutrition, or differences in food intake caused the effect.

13 Sep 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026